Morphine Market Research Report—Global Forecast till 2027

Global Morphine Market: By Dosage Form (Injection, Oral), By Application (Pain Management, Diarrhea Suppressant, Cold &Cough Suppressant), By End User (Hospitals& Clinics, Ambulatory Surgical Centers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (North America, Europe, Asia-Pacific, Rest of the World)—Forecast to 2027

ID: MRFR/HC/9162-HCR | August 2021 | Region: Global | 120 pages

Market Forecast


The global morphine market is expected to cross ~USD 33,650 million by 2027 at a CAGR of ~7.8%. 


Market Overview:


Morphine is a narcotic and analgesic substance derived from opioids to treat severe pain, and it belongs to the class of drugs known as narcotic analgesics. Morphine increasespain tolerance.


The morphine market is projected to record a CAGR of nearly ~7.8% during the forecast period. The increase in the use of morphine for pain management is a key factor contributing to the market growthsincemorphine is one of the most powerful pain relievers. Furthermore, theincreasing rate of legalization of potent opioids for medical use in various emerging countries by governments is expected to create significant opportunities for business expansion for existing players and enable easy entrance for new players in the global morphine market. Furthermore, increasing R&D activities for the development of novel products is another factor expected to offer lucrative opportunitiesfor the players in the market.


COVID-19 Analysis


Chronic pain management during the COVID-19 pandemic is challenging, owing to the changes in the healthcare delivery system due to safety precautions and social distancing. Whereas chronic pain is a major problem that affects 13.5% to 47% of the general population and can carry a substantial financial burden.Furthermore, elective surgeries and consultations were also canceled; nearly 88% of the cancer care centers faced challenges in delivering usual cancer care due to lack of personal protective equipment and staff shortage,which has had an impact on hospital and pain clinics, ultimately hampering the morphine market


In terms of the supply chain, more than 95% of morphine originates in Afghanistan, Mexico, and Myanmar. In all these three countries, the opium poppy is grown in fields, and harvesting opium is a labor-intensive activity. However, the COVID-19 crisis hinders opium production in several ways, such as the availability of workers reduced, reduced trade due to strict border controls, and laboratories facing shortages of chemicals due to lockdown measures. Hence, reducing imports and exports between borders may cause supply chain disruptions, resulting in a significant loss for morphine suppliers.


Market Dynamics


Drivers


  • Growing prevalence of orthopedic illnesses across the globe


The rising prevalence of orthopedic illnesses such as arthritis, elbow pain, fibromyalgia, and osteoporosis are the key drivers of the morphine market expansion. According to the World Health Organization, by 2050, 130 million people will suffer from osteoarthritis worldwide, of whom the disease will severely disable 40 million. Hence, the increasing usage of morphine in pain management is boosting the market growth.



  • Increasing cancer population leading to fuel morphine demand


An increase in the incidence of cancer is expected to boost the morphine market growth across the world.The increase in the incidence rate of cancer is explained below:
According to World Health Organization (WHO) figures, cancer is the primary or second leading cause of death in 112 of 183 nations before the age of 70. Overall, the global burden of cancer incidence and mortality is rapidly increasing; this reflects both population aging and expansion, as well as changes in the prevalence and distribution of the main risk factors for cancer
Similarly, according to the data from National Cancer Registry Programme (NCRP), Indian Council of Medical Research, the projected incidence of patients with cancer for 2020 in India in males was 679,421 and in females was 712,758
GLOBOCAN 2020 estimates of cancer incidence produced by the International Agency for Research on Cancer state worldwide, an estimated 19.3 million new cancer cases in 2020
Rates of obesity in adolescents and young adults have increased considerably in recent decades. For example, in 1998, 30.5% of young people were obese, compared to 42.4% in 2018. Given colorectal cancer's strong link to obesity, the increasing obesity rates among adolescents and young adults are likely to increase cancer rates as well


  • Increase in the elderly population


Market Restraints


  • The addictive nature of the drug restricts the growth of the global morphine market


Morphine is a pain reliever that can be used to treat moderate to severechronic pain. It's also used to manage pain after major surgeries, cancer-related pain, and shortness of breath. However, morphine can be highly addictive due to the rapid development of tolerance to it. When someone abuses this potent narcotic regularly, tolerance is usually the first step in developing an addiction. Moreover, to feel the effects of morphine,needed higher doses. When morphine users acquire a tolerance, they will experience withdrawal symptoms if they don't take it, making it difficult to quit. Furthermore, psychological dependence on morphine often develops shortly after the physical dependence.


  • Strict government regulations and side effects associated with morphine drugs


Value Chain Analysis:

The global morphine market is growing steadily and is expected to continue growing at the same rate in the near future. This is due to theincrease in the use of morphine for pain management, improving regulations regarding morphine, established healthcare infrastructure, and the availability of better medical facilities, along with increasing patient pool with cancer,orthopedic illnesses, and other chronic diseases. The value chain analysis for the global morphine market comprises five major components: the procurement of raw materials, R&D, manufacturing of the products, distribution and sales, and post-sales monitoring.


Segment Overview


By Dosage form



  • Injection: Patients who are vomiting, unconscious, or in case of emergency, morphineis given by injection into a vein, into a muscle, or under the skin.

  • Oral: The oral segment is expected to witness high growth in the global morphine market, owing to the increasing prescription and capability of morphine as strong pain relievers among pharmacists across the globe.


By Application


  • Pain Management: Morphine is a pain reliever that is used to treat moderate to severe pain. Extended-release morphine pills and capsules are only used to treat severe pain that is uncontrollable with other pain relievers. In addition, opioids play a vital role in acute post-operative settings to provide adequate analgesia. According to the International Osteoporosis Foundation, osteoporosis is one of the most important public health issues among women, impacting more than 30% of the population in the US and Europe each year and resulting in many fractures. According to data, the increasing prevalence of the disease with pain increases the segment growth. The pain management segment is further sub-segmented into cancer pain, neuropathic pain, osteoarthritis pain, and other pain management.

  • Diarrhea Suppressant: Diarrhea is a common and serious complication among cancer patients. It could be caused by a local infection, systemic inflammation, and side effect of radiotherapy or chemotherapy. Morphine acts on mu-receptors in the intestine, slowing intestinal transit time and boosting net absorption. The role of tincture of opium-like morphine (10 mg/mL morphine) in the treatment of diarrhea has been documented by the European Society for Medical Oncology (ESMO)

  • Cold &Cough Suppressant: Cough is prevalent in around 65% of patients with lung cancer and 70% of patients with COPD. Morphine sulfate is an effective antitussive in intractable chronic cough.


By End User


  • Hospitals & Clinics: The advancement in the hospital infrastructure across the globe is driving the morphine market. As the number of orthopedicdisorders and cancer patients increases, the demand for morphine in hospitals& clinics is also positively impacted. Hospitals& clinics held the majority share in 2020 due to the high orthopedic procedures & cancer treatment carried out in hospitals and clinics due to rising incidents ofcancer andorthopedicdisorders.

  • Moreover, according to the National Health Service report of 2018, in the United Kingdom, more than 10 million people have arthritis or other similar conditions that affect the joints

  • Ambulatory Surgical Centers: Outpatient services can encompass a wide range of procedures, such as surgeries, minimally invasive therapies, and other procedures.Moreover, ambulatory surgery centers are designed to maximize the efficiency of health care delivery, thus driving the growth of this segment


By Distribution Channel


  • Hospital Pharmacies The hospital pharmacies segment held a significant market share in 2020.Because most hospitals have in-house pharmacies, the necessity for a prescription for chemotherapy-related pain and other types of chronic pain in orthopedic disorders, such as arthritis, fibromyalgia, osteoporosis, and elbow pain, boosts the market for hospital pharmacies.

  • Online Stores:Online stores are convenient, time-saving, and cost-efficient; hence, this is expected to be the fastest-growing segment during the forecast period.

  • Retail Pharmacies:An independent pharmacy, a supermarket pharmacy, a chain pharmacy, or a mass merchandiser pharmacy with a state license to distribute drugs to the general public at retail pricing is referred to as a retailpharmacy.The growth of the retail pharmacies segment owes to the ease of accessibility of these distribution channelsespecially in rural areas and tier-II cities in the developing as well as under-developed economies.


Regional Analysis

North America



  • The increasing prevalence of arthritis and other inflammatory disorders in the regionis driving the North American Morphine Market

  • North America held the largest morphine market share in 2020. The market growth is attributed to the factors such as the presence of key players, the increasing prevalence of arthritis and other inflammatory disorders in the region, and established healthcare infrastructure. Furthermore, favorable government initiatives, an increase in the number of research partnerships, and increasing prescription of painkillers are the drivers expected to increase the market growth in this region.


Asia-Pacific


  • The increasing prevalence of chronic diseases is fueling the Asia-Pacific MorphineMarket

  • The Asia-Pacific morphine market is projected to be the fastest-growing regional market. The increasing prevalence of chronic diseases such as cardiovascular disorders,rising patient population, and new treatment methods are the major drivers for market growth. Moreover, rising healthcare expenditure in the region is driving the growth of the morphine market in the Asia Pacific region.


Competitive Landscape


  • The morphine market is greatly consolidated in nature, with the presence of leading players operating in this space. They focus on research & development activities majorly for pain management and other therapeutic applications such as cough and diarrhea suppression in various clinical and research fields. In addition, the market players are offering mergers and acquisitions, contractual agreements, new product launches, increasing investments, and partnering with other players to expand their global footprint.Moreover, in July 2020, researchers from the Cohen Children's Medical Center, New York, revealed that the use of intrathecal morphine after the surgical treatment of adolescent idiopathic scoliosis patients could help curb hospital costs and control post-operative pain in better ways. This also results in a lower opioid requirement in a significant way than patient-controlled analgesia.


List of Key Companies Covered in this Report:


  • Mallinckrodt Pharmaceuticals (Ireland)

  • Alcaliber (Spain)

  • Purdue Pharma (US)

  • Sanofi Winthrop Industrie (France)

  • Macfarlan Smith (UK)

  • Sun Pharmaceutical Industries (India)

  • Qinghai Pharmaceutical (China)

  • Northeast Pharmaceutical Group (China)

  • Pfizer Inc. (US)

  • Verve Health Care Ltd. (India)

  • Johnson Matthey Fine Chemicals (UK)

  • Manus Aktteva Biopharma LLP (India)

  • Mayne Pharma Group Limited (Australia)

  • Daiichi Sankyo Inc. (Japan)

  • Taj Pharmaceuticals Limited (India)


Recent Developments


  • In May 2021, Amphastar Pharmaceuticals (US) Received FDA Approval for Morphine Sulfate Injection.

  • In September 2018, Purdue Pharma (US) patented a new form of buprenorphine which controls cravings and is used to treat addiction to opioids such as OxyContin.


Report Overview


  • The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the rest of the world. The report analyzes market drivers, restraints, opportunities, challenges, Porters Five Forces, Value Chain, and impact of COVID-19 on the market


Scope of the Report & Segmentation

By Dosage Form



  • Injection

  • Oral

  • Other Dosage Forms


By Application


  • Pain Management

    • Cancer Pain

    • Neuropathic Pain

    • Osteoarthritis Pain

    • Other Pain Management



  • Diarrhea Suppressant

  • Cold & Cough Suppressant

  • Others


By Distribution Channel


  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Others


By End User


  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027:~USD 33,650 Million
  CAGR   ~7.8%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018-2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Dosage Form, Application, Distribution Channel, and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and the rest of the World (RoW)
  Key Vendors   • Mallinckrodt Pharmaceuticals (Ireland) • Alcaliber (Spain) • Purdue Pharma (US) • Sanofi Winthrop Industrie (France) • Macfarlan Smith (UK) • Sun Pharmaceutical Industries (India) • Qinghai Pharmaceutical (China) • Northeast Pharmaceutical Group (China) • Pfizer Inc. (US) • Verve Health Care Ltd. (India) • Johnson Matthey Fine Chemicals (UK) • MANUS AKTTEVA BIOPHARMA LLP (India) • Mayne Pharma Group Limited (Australia) • Daiichi Sankyo Inc. (Japan) • Taj Pharmaceuticals Limited (India)
  Key Market Opportunities   
  Key Market Drivers   • Growing prevalence of orthopedic illnesses across the globe • Increasing cancer population leading to fuel morphine demand


TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. ForecastingTechniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL MORPHINE MARKET, BY DOSAGE FORM

6.1. Overview

6.2. Injection

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3. Oral

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4. Other Dosage Forms

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7. GLOBAL MORPHINE MARKET, BY APPLICATION

7.1. Overview

7.2. Pain Management

7.2.1. Cancer Pain

7.2.2. Neuropathic Pain

7.2.3. Osteoarthritis Pain

7.2.4. Other Pain Management

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.3. Diarrhea Suppressant

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.4. Cold and Cough Suppressant

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8. GLOBAL MORPHINE MARKET, BY END USER

8.1. Overview

8.2. Hospitals& Clinics

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.3. Ambulatory Surgical Centres

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.4. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9. GLOBAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL

9.1. Overview

9.2. Hospital Pharmacies

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.3. Retail Pharmacies

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.4. Online Pharmacies

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

10. GLOBAL MORPHINE MARKET, BY REGION

10.1. Overview

10.2. North America

10.2.1. US

10.2.2. Canada

10.3. Europe

10.3.1. Germany

10.3.2. France

10.3.3. Italy

10.3.4. Spain

10.3.5. UK

10.3.6. Rest of Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Rest of the World

10.5.1. Middle East

10.5.2. Africa

10.5.3. Latin America

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Morphine Market

11.5. Competitive Benchmarking

11.6. Leading Players in terms of Number of Developments in the Global Morphine Market

11.7. Key developments and Growth Strategies

11.7.1. New ProductLaunch/Service Deployment

11.7.2. Merger &Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales & Operating Income, 2020

11.8.2. Major Players R&D Expenditure, 2020

12. COMPANY PROFILES

12.1. Mallinckrodt Pharmaceuticals

12.1.1. Company Overview

12.1.2. Product Offered

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Alcaliber

12.2.1. Company Overview

12.2.2. Products Offered

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Purdue Pharma

12.3.1. Company Overview

12.3.2. Products Offered

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Sanofi Winthrop Industrie

12.4.1. Company Overview

12.4.2. Products Offered

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Macfarlan Smith

12.5.1. Company Overview

12.5.2. Products Offered

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Sun Pharmaceutical Industries

12.6.1. Company Overview

12.6.2. Products Offered

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Qinghai Pharmaceutical

12.7.1. Company Overview

12.7.2. Products Offered

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Northeast Pharmaceutical Group

12.8.1. Company Overview

12.8.2. Products Offered

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Pfizer Inc.

12.9.1. Company Overview

12.9.2. Products Offered

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Verve Health Care Ltd.

12.10.1. Company Overview

12.10.2. Products Offered

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. Johnson Matthey Fine Chemicals

12.11.1. Company Overview

12.11.2. Products Offered

12.11.3. Financial Overview

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Manus Aktteva Biopharma LLP

12.12.1. Company Overview

12.12.2. Products Offered

12.12.3. Financial Overview

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. Mayne Pharma Group Limited

12.13.1. Company Overview

12.13.2. Products Offered

12.13.3. Financial Overview

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. Daiichi Sankyo Inc.

12.14.1. Company Overview

12.14.2. Products Offered

12.14.3. Financial Overview

12.14.4. Key Developments

12.14.5. SWOT Analysis

12.14.6. Key Strategies

12.15. Taj Pharmaceuticals Limited

12.15.1. Company Overview

12.15.2. Products Offered

12.15.3. Financial Overview

12.15.4. Key Developments

12.15.5. SWOT Analysis

12.15.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL MORPHINE MARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL MORPHINE MARKET ESTIMATES &FORECAST, 2018–2027 (USD MILLION)

TABLE 3 GLOBAL MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL MORPHINE MARKET, BY APPLICATION,2018–2027 (USD MILLION)

TABLE 5 GLOBAL MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 6 GLOBAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 7 NORTH AMERICA: MORPHINE MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 8 NORTH AMERICA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 9 NORTH AMERICA MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 10 NORTH AMERICA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 11 NORTH AMERICA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 12 US: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 13 US MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 14 US: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 15 US: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 16 CANADA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 17 CANADA MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 18 CANADA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 19 CANADA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 20 EUROPE: MORPHINE MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 21 EUROPE: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 22 EUROPE: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 23 EUROPE: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 24 EUROPE: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 25 GERMANY: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 26 GERMANY: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 27 GERMANY: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 28 GERMANY: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 29 FRANCE: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 30 FRANCE: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 31 FRANCE: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 32 FRANCE: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 33 ITALY: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 34 ITALY: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 35 ITALY: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 36 ITALY: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 37 SPAIN: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 38 SPAIN: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 39 SPAIN: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 40 SPAIN: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 41 UK: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 42 UK: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 43 UK: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 44 UK: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 45 REST OF EUROPE: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 46 REST OF EUROPE: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 47 REST OF EUROPE: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 48 REST OF EUROPE: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 49 ASIA-PACIFIC: MORPHINE MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 50 ASIA-PACIFIC: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 51 ASIA-PACIFIC: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 52 ASIA-PACIFIC: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 53 ASIA-PACIFIC: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 54 JAPAN: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 55 JAPAN: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 56 JAPAN: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 57 JAPAN: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 58 CHINA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 59 CHINA: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 60 CHINA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 61 CHINA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 62 INDIA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 63 INDIA: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 64 INDIA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 65 INDIA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 66 AUSTRALIA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 67 AUSTRALIA: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 68 AUSTRALIA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 69 AUSTRALIA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 70 SOUTH KOREA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 71 SOUTH KOREA: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 72 SOUTH KOREA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 73 SOUTH KOREA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 74 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 75 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 76 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 77 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 78 REST OF THE WORLD: MORPHINE MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 79 REST OF THE WORLD: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 80 REST OF THE WORLD: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 81 REST OF THE WORLD: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 82 REST OF THE WORLD: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 83 MIDDLE EAST: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 84 MIDDLE EAST: MORPHINE MARKET,BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 85 MIDDLE EAST: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 86 MIDDLE EAST: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 87 AFRICA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 88 AFRICA: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 89 AFRICA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 90 AFRICA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

TABLE 91 LATIN AMERICA: MORPHINE MARKET, BY DOSAGE FORM, 2018–2027 (USD MILLION)

TABLE 92 LATIN AMERICA: MORPHINE MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 93 LATIN AMERICA: MORPHINE MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 94 LATIN AMERICA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MORPHINE MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MORPHINE MARKET

FIGURE 4 GLOBAL MORPHINE MARKET SHARE, BY DOSAGE FORM, 2020 (%)

FIGURE 5 GLOBAL MORPHINE MARKET SHARE, BY APPLICATION, 2020(%)

FIGURE 6 GLOBAL MORPHINE MARKET SHARE, BY END USER, 2020(%)

FIGURE 7 GLOBAL MORPHINE MARKET SHARE, BYDISTRIBUTION CHANNEL, 2020 (%)

FIGURE 8 GLOBAL MORPHINE MARKET SHARE, BY REGION, 2020(%)

FIGURE 9 NORTH AMERICA: MORPHINE MARKET SHARE, BY REGION, 2020(%)

FIGURE 10 EUROPE: MORPHINE MARKET SHARE, BY REGION, 2020(%)

FIGURE 11 ASIA-PACIFIC: MORPHINE MARKET SHARE, BY REGION, 2020(%)

FIGURE 12 REST OF THE WORLD: MORPHINE MARKET SHARE, BY REGION, 2020(%)

FIGURE 13 GLOBAL MORPHINE MARKET: COMPANY SHARE ANALYSIS, 2020(%)

FIGURE 14 MALLINCKRODT PHARMACEUTICALS: KEY FINANCIALS

FIGURE 15 MALLINCKRODT PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 16 MALLINCKRODT PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 17 ALCALIBER: KEY FINANCIALS

FIGURE 18 ALCALIBER: SEGMENTAL REVENUE

FIGURE 19 ALCALIBER: REGIONAL REVENUE

FIGURE 20 PURDUE PHARMA: KEY FINANCIALS

FIGURE 21 PURDUE PHARMA: SEGMENTAL REVENUE

FIGURE 22 PURDUE PHARMA: REGIONAL REVENUE

FIGURE 23 SANOFI WINTHROP INDUSTRIE: KEY FINANCIALS

FIGURE 24 SANOFI WINTHROP INDUSTRIE: SEGMENTAL REVENUE

FIGURE 25 SANOFI WINTHROP INDUSTRIE: REGIONAL REVENUE

FIGURE 26 MACFARLAN SMITH: KEY FINANCIALS

FIGURE 27 MACFARLAN SMITH: SEGMENTAL REVENUE

FIGURE 28 MACFARLAN SMITH: REGIONAL REVENUE

FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES: KEY FINANCIALS

FIGURE 30 SUN PHARMACEUTICAL INDUSTRIES: SEGMENTAL REVENUE

FIGURE 31 SUN PHARMACEUTICAL INDUSTRIES: REGIONAL REVENUE

FIGURE 32 QINGHAI PHARMACEUTICAL: KEY FINANCIALS

FIGURE 33 QINGHAI PHARMACEUTICAL: SEGMENTAL REVENUE

FIGURE 34 QINGHAI PHARMACEUTICAL: REGIONAL REVENUE

FIGURE 35 NORTHEAST PHARMACEUTICAL GROUP: KEY FINANCIALS

FIGURE 36 NORTHEAST PHARMACEUTICAL GROUP: SEGMENTAL REVENUE

FIGURE 37 NORTHEAST PHARMACEUTICAL GROUP: REGIONAL REVENUE

FIGURE 38 PFIZER INC.: KEY FINANCIALS

FIGURE 39 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 40 PFIZER INC.: REGIONAL REVENUE

FIGURE 41 VERVE HEALTH CARE LTD.: KEY FINANCIALS

FIGURE 42 VERVE HEALTH CARE LTD.: SEGMENTAL REVENUE

FIGURE 43 VERVE HEALTH CARE LTD.: REGIONAL REVENUE

FIGURE 44 JOHNSON MATTHEY FINE CHEMICALS: KEY FINANCIALS

FIGURE 45 JOHNSON MATTHEY FINE CHEMICALS: SEGMENTAL REVENUE

FIGURE 46 JOHNSON MATTHEY FINE CHEMICALS: REGIONAL REVENUE

FIGURE 47 MANUS AKTTEVA BIOPHARMA LLP: KEY FINANCIALS

FIGURE 48 MANUS AKTTEVA BIOPHARMA LLP: SEGMENTAL REVENUE

FIGURE 49 MANUS AKTTEVA BIOPHARMA LLP: REGIONAL REVENUE

FIGURE 50 MAYNE PHARMA GROUP LIMITED: KEY FINANCIALS

FIGURE 51 MAYNE PHARMA GROUP LIMITED: SEGMENTAL REVENUE

FIGURE 52 MAYNE PHARMA GROUP LIMITED: REGIONAL REVENUE

FIGURE 53 DAIICHI SANKYO INC.: KEY FINANCIALS

FIGURE 54 DAIICHI SANKYO INC.: SEGMENTAL REVENUE

FIGURE 55 DAIICHI SANKYO INC.: REGIONAL REVENUE

FIGURE 56 TAJ PHARMACEUTICALS LIMITED: KEY FINANCIALS

FIGURE 57 TAJ PHARMACEUTICALS LIMITED: SEGMENTAL REVENUE

FIGURE 58 TAJ PHARMACEUTICALS LIMITED: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.